RXRX Stock Rises As Tempus AI Deal Resets Growth Story

Recursion Pharmaceuticals Inc. stocks have been trading up by 5.14 percent amid upbeat coverage of its AI-driven drug discovery advances.

Live Update At 16:46:46 EDT: On Thursday, September 24, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 5.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been grinding higher through September, and the tape tells the story. From August 31, 2026, Recursion Pharmaceuticals stock has pushed from about $3.40 into the high $3s, closing near $3.89 on 2026/09/24. That’s a steady uptrend, not a meme-style spike.

Intraday, RXRX traded in a tight channel between roughly $3.65 and $3.90, with a late-day push toward the highs. This kind of controlled range, with strong closes near the top, often shows accumulation rather than pure day-trader churn.

Fundamentally, RXRX is still a high-burn, early-revenue AI‑driven biotech. The latest quarterly numbers show about $7.3M in revenue against a net loss of roughly $131M, with EBITDA deeply negative at about -$112.5M. Margins are brutal and solidly red. But RXRX also reports a hefty cash pile near $546M and very low debt, with a current ratio around 5, giving the company runway to execute its platform strategy.

More Breaking News

• PATH Stock Slides As Analysts Cut Price Targets
• WETO Stock Slides As Traders Watch Key Support Levels
• LU Stock Holds Ground As Ownership Shifts And Overhaul Nears Completion
• MARA Holdings Drops As JPMorgan Slashes Price Target

For traders, that mix — heavy losses, strong balance sheet, and visible tech partnerships — sets RXRX up as a classic high-beta, news‑driven vehicle where headlines matter more than current earnings.

Why Traders Are Watching RXRX After The Tempus Deal

RXRX just gave active traders a clear catalyst: an extended and reshaped deal with Tempus AI. Recursion Pharmaceuticals pushed its data license partnership out to November 2029 and locked in $42M in license payments over the next three years. The headline total is lower than the prior “up to $84M,” but this time the cash is committed and more predictable.

For RXRX, that matters. The company is running a capital‑intensive AI drug discovery model with deep losses and big R&D spend. Having Tempus on the hook for scheduled payments helps smooth the revenue line and supports the story that RXRX’s platform has commercial value today, not just far in the future. Traders care because recurring, contracted revenue can support higher confidence when the next wave of volatility hits.

The other key twist is technology. RXRX granted Tempus a new non‑exclusive worldwide license to its proprietary RNA foundation model, TxFM. That’s the core engine behind part of Recursion Pharmaceuticals’ AI biology thesis. By licensing TxFM, RXRX is signaling that its models are valuable enough for a serious external partner to pay for long term.

The stock’s reaction backs that up. RXRX gained about 2.6% after the announcement, a clean confirmation that the market liked the trade‑off: lower theoretical upside in exchange for more certain cash and deeper AI integration with Tempus. On the margins, several Form 4 filings showed insider ownership shifts in RXRX, but without detail on whether they were buys or sells, traders should treat them as background noise next to the Tempus headline. The real story here is platform validation plus contracted dollars through 2029.

Conclusion

RXRX is acting exactly like a news‑sensitive growth name should. The chart shows a steady climb from the low $3s to the high $3s over the past few weeks, capped by that 2.6% pop on the Tempus deal. Recursion Pharmaceuticals gave the market what it wants from a story‑driven biotech: longer‑dated visibility, a real partner in Tempus AI, and clear proof that its RNA model TxFM has licensing value.

At the same time, the financials keep RXRX squarely in speculative territory. Losses are large, margins are ugly, and the business leans heavily on its cash balance and future deals. That’s exactly why traders flock to names like Recursion Pharmaceuticals — they move hard when headlines hit. The extended Tempus agreement and $42M in committed fees over three years provide a concrete catalyst that can anchor the next leg of trading. As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” For many short‑term RXRX traders, that pattern is the recurring cycle of catalysts, volume spikes, and sharp moves that surround headline‑driven names.

For active RXRX traders, the playbook is the same as always in this community: respect the volatility, watch the levels, and do not marry the stock. As Tim Sykes likes to remind his students, “Hype creates opportunities, but discipline keeps you in the game.” RXRX’s Tempus catalyst is the hype; tight risk management and clear trading plans are how serious traders will try to turn that hype into actual P&L.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.